Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
1377323 | Bioorganic & Medicinal Chemistry Letters | 2008 | 4 Pages |
Abstract
Novel 4-anilino-1H-pyrazolo[3,4-d]pyrimidines have been synthesized and evaluated in vitro for erbB2 and EGFR kinase inhibition. A representative compound displaying oral bioavailability in rat and dog illustrates the potential of this series to provide orally active erbB2 inhibitors.
Graphical abstractNovel 4-anilino-1H-pyrazolo[3,4-d]pyrimidines have been synthesized and evaluated in vitro for erbB2 and EGFR kinase inhibition. A representative compound displaying oral bioavailability in rat and dog illustrates the potential of this series to provide orally active erbB2 inhibitors.Figure optionsDownload full-size imageDownload as PowerPoint slide
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Richard Ducray, Peter Ballard, Bernard C. Barlaam, Mark D. Hickinson, Jason G. Kettle, Donald J. Ogilvie, Catherine B. Trigwell,